Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. reports developments as a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. Company updates center on NKX019, an investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases, and on the Ntrust-1 and Ntrust-2 clinical studies.
Recurring news themes include FDA protocol discussions, outpatient dosing plans, dose-escalation updates, B-cell depletion data, preclinical and clinical presentations, quarterly financial results, cash runway commentary, workforce and operating updates, and participation in healthcare and investor conferences.
Nkarta has initiated the Ntrust-1 clinical trial for NKX019 in lupus nephritis with the first patient now in screening.
The company has received FDA clearance for a second IND application for NKX019, enabling the launch of Ntrust-2 to treat systemic sclerosis, myositis, and vasculitis.
Both trials aim to assess the safety and efficacy of NKX019, an allogeneic CAR NK-cell therapy designed to target CD19-positive cells in B-cell mediated diseases.
Data from these trials are expected by 2025.
NKX019 leverages fludarabine-free lymphodepletion and offers on-demand dosing capabilities.
The Ntrust-1 trial involves administering NKX019 on Days 0, 7, and 14, while Ntrust-2 will adopt a different dosing schedule.
Each trial will initially enroll up to 12 patients.
Nkarta, a clinical-stage biopharmaceutical firm, has announced the addition of Dr. George Vratsanos to its board of directors. Dr. Vratsanos is a seasoned translational immunology expert, currently serving as Chief Medical Officer and Head of R&D at Jnana Therapeutics. His extensive R&D experience includes leadership roles at Janssen Pharmaceuticals, Novartis, Roche, and Bristol Myers Squibb. Dr. Vratsanos holds degrees from NYU School of Medicine, Yale University, Vanderbilt University, and Columbia University.
Nkarta is focused on developing NK cell therapies to treat autoimmune diseases, including lupus. Their candidate, NKX019, aims to treat lupus nephritis. Dr. Vratsanos expressed enthusiasm for joining Nkarta, highlighting the potential of NK cell therapy to treat autoimmune diseases with fewer safety concerns than other therapies.
Nkarta, Inc. (Nasdaq: NKTX) reported strong financial results for Q1 2024 with a cash balance of $450.0 million as of March 31, 2024. The company is developing NKX019, an off-the-shelf cell therapy candidate for autoimmune diseases like lupus nephritis and non-Hodgkin lymphoma. NKX019 has shown promising results in clinical trials, with plans for expansion into other autoimmune diseases. Nkarta completed a recent $240.1 million offering, strengthening its balance sheet. Financial guidance indicates cash reserves to fund operations into late 2027.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.